Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma (Registro nro. 22723)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03160nam a2200289 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260804122828.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Choueiri, Toni K. |
| Rol del Autor | Autor |
| 9 (RLIN) | 53653 |
| 245 ## - Titulo | |
| Titulo | Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma |
| 300 ## - Páginas | |
| Paginación | páginas: 32-43 |
| 520 ## - Resumen | |
| Resumen | Background: <br/>Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease. Adjuvant pembrolizumab with belzutifan may further improve outcomes in patients with clear-cell renal-cell carcinoma at increased risk for recurrence.<br/>Methods: <br/>In this phase 3, double-blind trial, we randomly assigned participants in a 1:1 ratio to receive intravenous pembrolizumab at a dose of 400 mg every 6 weeks (≤9 doses) and either daily oral belzutifan at a dose of 120 mg (pembrolizumab–belzutifan) or placebo (pembrolizumab–placebo) for up to 1 year. The primary end point was disease-free survival as assessed by the investigator; secondary end points included overall survival and safety.<br/>Results: <br/>A total of 921 participants were assigned to receive pembrolizumab–belzutifan and 920 were assigned to receive pembrolizumab–placebo. The median time from randomization to the data-cutoff date (August 23, 2025) was 28.4 months (range, 15.0 to 40.1). Disease-free survival was significantly higher with pembrolizumab–belzutifan than with pembrolizumab–placebo (hazard ratio for disease recurrence or death, 0.72; 95% confidence interval [CI], 0.59 to 0.87; two-sided P<0.001); the estimated 24-month disease-free survival was 80.7% and 73.7%, respectively. At this interim analysis with 29% of the final-analysis events observed, overall survival did not differ significantly between the groups (hazard ratio for death, 0.78; 95% CI, 0.51 to 1.19; two-sided P=0.24); the estimated 24-month overall survival was 96.2% with pembrolizumab–belzutifan and 95.7% with pembrolizumab–placebo. Adverse events of grade 3 or higher occurred in 52.1% of the participants who received pembrolizumab–belzutifan and in 30.2% of those who received pembrolizumab–placebo.<br/>Conclusions: <br/>Treatment with pembrolizumab–belzutifan led to significantly higher disease-free survival, with a greater risk of grade 3 or higher toxic effects, than treatment with pembrolizumab monotherapy after nephrectomy in participants with clear-cell renal-cell carcinoma at increased risk for recurrence. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CÁNCER GENITOURINARIO |
| 9 (RLIN) | 53654 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | NEFROLOGÍA GENERAL |
| 9 (RLIN) | 53655 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS DE ONCOLOGÍA |
| 9 (RLIN) | 53656 |
| 700 ## - Autor Personal | |
| Autor Personal | Motzer, Robert J. |
| 9 (RLIN) | 53657 |
| 700 ## - Autor Personal | |
| Autor Personal | Karam, Jose A. |
| 9 (RLIN) | 53658 |
| 700 ## - Autor Personal | |
| Autor Personal | Yip, Wesley |
| 9 (RLIN) | 53659 |
| 700 ## - Autor Personal | |
| Autor Personal | Suárez, Cristina |
| 9 (RLIN) | 53660 |
| 700 ## - Autor Personal | |
| Autor Personal | Ye, Dingwei |
| 9 (RLIN) | 53661 |
| 700 ## - Autor Personal | |
| Autor Personal | He, Zhisong |
| 9 (RLIN) | 53662 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22634 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM001 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | sqb |
No hay ítems disponibles.